12/23
09:02 am
imrx
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 [Yahoo! Finance]
Medium
Report
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 [Yahoo! Finance]
12/23
08:00 am
imrx
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Medium
Report
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
12/20
01:30 am
imrx
Medium
Report
12/17
05:28 pm
imrx
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA [Yahoo! Finance]
Medium
Report
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA [Yahoo! Finance]
12/17
04:05 pm
imrx
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
Medium
Report
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
12/16
04:37 pm
imrx
Immuneering (NASDAQ:IMRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Immuneering (NASDAQ:IMRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
08:37 am
imrx
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
Low
Report
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
12/16
08:00 am
imrx
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Medium
Report
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
12/15
09:31 am
imrx
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO) [Yahoo! Finance]
Medium
Report
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO) [Yahoo! Finance]
12/12
10:47 am
imrx
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Medium
Report
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
11/25
09:08 am
imrx
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
imrx
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
11/15
01:42 am
imrx
11/13
09:01 am
imrx
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Medium
Report
Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
11/12
09:14 pm
imrx
Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:05 pm
imrx
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
Low
Report
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
11/11
05:42 pm
imrx
Immuneering Q3 2025 Earnings Preview [Seeking Alpha]
Low
Report
Immuneering Q3 2025 Earnings Preview [Seeking Alpha]
11/4
04:05 pm
imrx
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
Low
Report
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
11/1
06:55 am
imrx
Immuneering (NASDAQ:IMRX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Immuneering (NASDAQ:IMRX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/31
08:06 am
imrx
Immuneering (NASDAQ:IMRX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $15.00 price target on the stock.
Medium
Report
Immuneering (NASDAQ:IMRX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $15.00 price target on the stock.
10/29
09:03 am
imrx
Immuneering (NASDAQ:IMRX) was given a new $12.00 price target on by analysts at Mizuho.
Medium
Report
Immuneering (NASDAQ:IMRX) was given a new $12.00 price target on by analysts at Mizuho.
10/12
03:39 pm
imrx
SA Asks: What's the most attractive biotech stock right now? [Seeking Alpha]
Low
Report
SA Asks: What's the most attractive biotech stock right now? [Seeking Alpha]
10/8
12:25 pm
imrx
Immuneering (NASDAQ:IMRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Immuneering (NASDAQ:IMRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
10:21 am
imrx
OS endpoint focus will realign industry to “ultimate goal” [Yahoo! Finance]
Medium
Report
OS endpoint focus will realign industry to “ultimate goal” [Yahoo! Finance]
9/30
12:00 pm
imrx
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) [Yahoo! Finance]
Medium
Report
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) [Yahoo! Finance]